We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Five Blue Cross Blue Shield health insurance plans have set up an independent company aimed at reducing drug costs by linking the prices with actual drug results. Read More
In the first-ever instance of a state and drugmaker reaching a deal over price-fixing litigation, Teva Pharmaceuticals has agreed to fork over $925,000 to the state of Mississippi to settle allegations of conspiring to set prices of generic drugs. Read More
The FDA released two memos from officials and a long review document late Tuesday, shining new light on internal agency discussions over the past two years regarding Biogen’s Aduhelm, the very expensive new Alzheimer’s disease (AD) drug that’s caused a firestorm of controversy since the FDA approved it June 7 against the advice of its 11-member advisory panel, three of whom resigned in protest after the approval. Read More
Sponsors developing drugs to treat breast cancer should consider including premenopausal women in their clinical trials and may be required to conduct postmarketing studies to analyze the long-term effects of these treatments, the FDA said in a final guidance. Read More
HHS has withdrawn an advisory opinion issued in late December stating that drugmakers must offer 340B drug discounts through contracting pharmacies. Read More
A substantial proportion of Medicare Part D spending purchases drugs with absent or low-quality cost-effectiveness analyses, and this lack of analyses may cause problems for developing policies that address value in drug spending. Read More
An FDA inspection of Dr. Reddy’s active pharmaceutical ingredient (API) manufacturing plant in Middleburgh, New York earlier this year found lapses in good manufacturing practice (GMP). Read More